Information Provided By:
Fly News Breaks for March 28, 2018
ABT, DXCM
Mar 28, 2018 | 08:37 EDT
Jefferies analyst Raj Denhoy says FDA clearance for Dexcom's (DXCM) G6 sensor slightly ahead of schedule provides another reason to stick with the shares. The approval closes a "key gap" relative to Abbott's (ABT) Libre, Denhoy tells investors in a research note. He believes an earlier launch of G6 "is now feasible," keeping Dexcom "insulated from share shifts." The analyst has a Buy rating on the shares with a $70 price target.